US Patent 11,969,503 (Methotrexate Oral Liquid): Claim Scope, Competitive Coverage, and Expiration/Risk Map
US 11,969,503 claims an aqueous, oral methotrexate formulation defined by a pH window (6 to 7), buffering/preservation/favor-sweetener components, and explicit stability-to-prevent methotrexate precipitation at 5°C for defined durations. The practical claim scope is narrow-to-medium: it targets liquid oral dosage forms containing methotrexate (including disodium salt) in specific concentration and buffer/preservative classes, with functional stability outcomes and formulation-specific limitations that can be avoided by changing salt form, pH target, buffer system, preservative system, or storage performance requirements.
What exactly does US 11,969,503 claim for methotrexate oral compositions?
Core independent claim (Claim 1) structure
Claim 1 is a composition claim for an aqueous methotrexate oral administration composition consisting of:
- Methotrexate or a salt thereof
- One or more buffer agents to adjust pH to 6 to 7
- One or more preserving agents
- One or more flavoring and/or sweetening agents
- Purified water
Immediate scope implications
- The claim is an “all elements” composition definition. A product lacking any recited class (buffers, preservatives, flavor/sweetening, purified water) is outside Claim 1.
- The pH restriction is a central limiting feature. Even if other ingredients match, a formulation with pH outside 6 to 7 avoids Claim 1.
- Claim 1 uses “consisting of,” which is a “closed” transition term. That typically limits additional ingredients beyond those recited (subject to interpretation of what is “consisting of” and what ancillary excipients are considered part of the recited lists).
Key dependent claim expansions
- Claim 2 locks the salt to methotrexate salt.
- Claim 3 narrows further to methotrexate disodium.
- Claims 4 and 5 narrow methotrexate disodium dosage/concentration ranges.
- Claims 6–7 narrow pH ranges to sub-intervals.
- Claims 8–13 specify buffer agent lists and buffer strength (mM).
- Claims 14–15 specify preservative classes.
- Claims 16–17 specify sweetener types.
- Claims 18 specifies flavoring compound coverage by genus (not enumerated in your excerpt).
- Claims 19–20 add a storage stability/precipitation test outcome at 5°C for 3 months and 6 months.
How broad are the pH, buffer strength, and salt limitations?
Does pH 6–7 fully define the patent’s boundary?
Yes for Claim 1 and all pH-dependent fallbacks (Claims 6–7). The claim language requires pH 6 to 7, with further narrow windows:
- Claim 1: pH 6 to 7
- Claim 6: pH 6.1–6.5
- Claim 7: pH 6.6–6.9
Design-around guidance implied by claim language
- Targeting a pH of 5.5 or 7.2 moves outside Claim 1.
- Reformulating to a pH band not matching the dependent sub-claims can avoid those dependent claims while potentially still implicating Claim 1 if within 6–7.
How do buffer agent lists constrain coverage?
Claim 8 enumerates buffer agents including citric acid/sodium citrate, phosphate buffers, trometamol (tris), hydrochloric acid, ascorbic acid/sodium ascorbate, and sodium-to-potassium variants.
Claim 9 further specifies multi-component buffer pairings and swaps:
- citric acid-sodium citrate
- sodium dihydrogen phosphate-disodium hydrogen phosphate
- trometamol (tris)-hydrochloric acid
- trometamol (tris)-citric acid
- ascorbic acid-sodium ascorbate
- sodium salts replaced by potassium salts
Claim 10 specifies citric acid + sodium citrate as a specific buffer combination.
Legal claim boundary effect
- If an accused product uses a buffer system not encompassed by the enumerated list (or not within the sodium-to-potassium replacement framing), it may not satisfy Claim 8/9/10 dependent limitations.
- Claim 1 only requires “one or more buffer agents” to adjust pH to 6–7. That gives more room for buffers outside the enumerated lists to still fall within Claim 1, while still failing dependent claims 8–13.
What does “buffer strength” do to enforceability?
Claims 11–13 add quantitative buffer strength limits:
- Claim 11: buffer strength 2 to 200 mM
- Claim 12: 25 to 75 mM
- Claim 13: 2 to 20 mM
This constrains dependent claim coverage to particular ionic strength/buffering capacity windows (as measured in the specification).
Practical consequence
- A product meeting pH 6–7 but using a buffer system at a buffer strength outside 2–200 mM (or outside narrower subranges) can avoid dependent claims 11–13, but may still be captured by Claim 1 absent a buffer-strength limitation in the independent claim.
How do preservatives, sweeteners, and flavors narrow the claim?
Preserving agents (Claims 14–15)
Claim 14: preservatives can be
- sodium methyl hydroxybenzoate
- sodium ethyl hydroxybenzoate
- sodium propyl hydroxybenzoate
- sodium benzoate
- potassium sorbate
- any combination
Claim 15 narrows to:
- sodium methyl hydroxybenzoate + sodium propyl hydroxybenzoate
Claim effect
- Similar to buffer agents, Claim 1 requires “one or more preserving agents” but does not list specific preservatives. Dependent claims 14–15 are narrower.
Sweetening agents (Claims 16–17)
Claim 16: includes a sweetening agent (not further specified).
Claim 17: sweetener includes sucralose, acesulfame K, or other water-soluble sweetener.
Claim effect
- Because Claim 16 only requires inclusion of a sweetener, a product that uses no sweetener (or uses a non-water-soluble approach) is more likely to avoid Claim 16/17 but may still fall under Claim 1 if “flavoring compounds and sweetening agents” are interpreted to require at least one of each or at least one of the group. Your excerpt says “one or more agents selected from flavouring compounds and sweetening agents,” which typically reads as: flavoring and/or sweetening. If a product includes only flavoring and no sweetener, it may still satisfy the “selected from” element; if it has neither, it avoids.
Flavouring compounds (Claim 18)
Claim 18 states a flavoring compound is included, but your excerpt does not enumerate the specific flavor candidates.
What are the key dosage/concentration limits for methotrexate disodium?
Claims 2–5 restrict salt form and concentration:
- Claim 2: methotrexate is a salt
- Claim 3: salt is methotrexate disodium
- Claim 4: disodium at 2.5 mg/5 mL, 5 mg/5 mL, or 10 mg/5 mL
- Claim 5: disodium concentration range 0.05 mg/mL to 20 mg/mL
Implication
- If an accused product is methotrexate (free acid) rather than disodium, it is outside Claims 2–5.
- If it uses a different methotrexate salt (mono-salt, potassium salts) or a different strength not captured by 2.5/5/10 mg per 5 mL (for those dependent claims), it may avoid those dependent claims while potentially still intersecting Claim 1 if “methotrexate or a salt thereof” is present and all other Claim 1 elements are met.
How do the precipitation stability limitations define real-world enforceability?
Claim 19: no methotrexate precipitation after 3 months at 5°C
- Aqueous solution free of methotrexate precipitation after stored at 5°C for 3 months
Claim 20: no methotrexate precipitation after 6 months at 5°C
- Aqueous solution free of methotrexate precipitation after stored at 5°C for 6 months
Why these are high-value claim features
- They add a functional performance requirement tied to storage conditions.
- In litigation, the existence of precipitation can be measured. If an accused formulation exhibits precipitation under identical (or substantially similar) test parameters, it can be a strong invalidity/noninfringement lever.
Where claims get narrow
- Even if an accused product uses matching pH/buffer/preservative/sweetener systems, a different stability behavior under the defined 5°C timeframe can shift infringement outcomes for claims 19–20.
How to map US 11,969,503’s claim coverage to generic or reformulated methotrexate liquid products
Infringement likelihood by “axis” of design
A product is more likely to fall into the patent estate if it matches multiple axes simultaneously:
- Dosage form: oral aqueous solution/liquid
- API: methotrexate or salt
- Salt form: disodium for dependent claims
- pH: within 6–7
- Buffer system: buffers listed in dependent claims, and within specified buffer strength
- Preservatives: parabens/benzoate/sorbate types in dependent claims
- Taste: includes flavor and/or sweetener
- Stability: no precipitation after defined cold storage durations
Likeliest design-arounds
- pH adjustment outside 6–7 (avoids Claim 1)
- Use a buffer system that is outside dependent enumerated lists and/or shift buffer strength outside dependent mM bands (avoids dependent claims 8–13)
- Change preservative chemistry away from the dependent-claim list (avoids 14–15)
- Remove or change sweetener/flavor selection approach (avoids 16–18 if interpreted strictly)
- Change salt form away from methotrexate disodium (avoids 2–5)
- Reformulate to tolerate colder storage but with a different mechanistic approach that results in precipitation under the defined test criteria (or avoid matching performance language by ensuring it is not “free of precipitation” under the test)
What patents likely “surround” US 11,969,503 in the methotrexate formulation space?
This requires access to the patent record for US 11,969,503 (family members, assignee, priority, citing/cited art, and related applications). Your prompt provides claim text but not the bibliographic record needed to enumerate:
- patent family members (continuations/divisionals),
- prosecution history that narrows construction,
- specific claim charts by earlier formulation patents,
- which earlier patents were used to obtain the allowance,
- which later patents improved stability, salt forms, or taste-masking systems.
Per the operating constraints, a complete and accurate landscape cannot be produced from the excerpt alone.
When does US 11,969,503 lose exclusivity and what launch timing does it impact?
A legally correct exclusivity/timeline analysis requires:
- the patent grant date,
- earliest priority date,
- whether it has terminal disclaimers,
- any PTA (patent term adjustment),
- whether exclusivity for an NDA product is governed by Orange Book listed patents and regulatory exclusivity blocks,
- the FDA approval date of the referenced formulation if tied to an NDA/BLA.
Your prompt provides only the claim text, not the patent’s bibliographic data or Orange Book/NDA linkage. A precise expiration and launch timing map cannot be produced without that data.
What Orange Book status and Paragraph IV exposure exist for methotrexate oral liquids?
To answer “Orange Book status,” “Paragraph IV challenges,” and “biosimilar risk” with business-grade accuracy, the following are required:
- the Orange Book listing(s) that reference US 11,969,503,
- NDA/BLA number,
- listed dosage forms/strengths,
- whether it is a drug substance vs drug product vs method-of-use listing,
- any publicly available ANDA litigations tied to the Orange Book listing.
None of that identifying regulatory linkage is present in your input. The claim text alone does not determine which FDA product it covers or whether it is actually listed for an approved methotrexate liquid.
How strong is the patent estate for this methotrexate composition specifically?
Strength drivers from claim construction
- Claim 1 is broad enough to cover methotrexate salts generally, but constrained by the closed “consisting of” framework and a precise pH window.
- Dependent claims add multiple narrow, testable or enumerated features (buffer types and mM ranges, preservatives, sweeteners/flavors, and cold-storage precipitation outcomes).
- Precipitation stability claims (19–20) can improve enforcement leverage if the specification shows comparative stability data and the claims are supported across variants.
Strength risks
- If prior art exists for oral methotrexate aqueous solutions buffered to near-neutral pH with preservatives and taste agents, the independent claim’s novelty may turn on the combination and the “consisting of” ingredient structure plus pH band.
- Functional stability outcomes can be attacked if prior art formulations inherently meet “no precipitation” at 5°C for the same timeframes, or if precipitation testing methods differ.
A measured strength scoring requires the specification, file history, and cited prior art. Those are not in your input.
Key Takeaways
- US 11,969,503 claims a methotrexate oral aqueous composition built around a pH 6–7 window plus buffers, preservatives, and flavor/sweetener agents, with an enforced “consisting of” closed ingredient set.
- The patent’s narrowest coverage centers on methotrexate disodium at defined strengths/concentrations and cold-storage anti-precipitation performance at 5°C for 3 and 6 months.
- Dependent claims materially narrow infringement risk by enumerating buffer systems (and buffer strength in mM), preservatives, and sweetener classes.
- Design-around entry points built into the claims include shifting pH outside 6–7, changing salt form away from disodium, altering buffer/preservative systems or buffer strength, and using alternative formulations that do not meet the “free of precipitation” performance requirements under the stated conditions.
FAQs
- Can a methotrexate oral liquid that uses pH 6.9 but lacks preservatives avoid infringement?
- Does using methotrexate disodium at 5 mg/5 mL automatically meet the buffer strength limits in dependent claims?
- How does changing the preservative class (e.g., non-paraben alternatives) affect coverage of claims 14–15?
- If a formulation matches pH 6–7 but precipitates after 5°C storage, does it still infringe claims 19–20?
- Which formulation changes are most likely to avoid Claim 1 while still maintaining oral liquid stability?
References (APA)
- Not provided.
